

研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Masaki A, <b>Ishida T</b> , Maeda Y, Suzuki S, Ito A, Takino H, Ogura H, Totani H, Yoshida T, Kinoshita S, Narita T, Ri M, Kusumoto S, Inagaki A, Komatsu H, Niimi A, <b>Ueda R</b> , Utsunomiya A, Inagaki H, <b>Iida S</b> .	Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma.	Clin Cancer Res.		Epub ahead of print	2015
<b>Ishida T</b> , Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, <b>Ueda R</b> .	Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive ATL: a randomized phase II study.	Br J Haematol.		672-82	2015
Ifuku H, Kusumoto S, Tanaka Y, Totani H, <b>Ishida T</b> , Okada M, Murakami S, Mizokami M, <b>Ueda R</b> , <b>Iida S</b> .	Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.	Hepatol Res.		Epub ahead of print	2015
Totani H, Kusumoto S, <b>Ishida T</b> , Masuda A, Yoshida T, Ito A, Ri M, Komatsu H, Murakami S, Mizokami M, <b>Ueda R</b> , Niimi A, Inagaki H, Tanaka Y, <b>Iida S</b> .	Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy.	Int J Hematol.	101	398-404	2015
Suzuki T, Kusumoto S, Masaki A, <b>Ishida T</b> , Inagaki H, <b>Iida S</b> , Morif.	CD30-positive primary bone marrow lymphoma mimicking Hodgkin lymphoma.	Int J Hematol.	101	109-11	2015
Eikawa S, Nishida M, Mizukami S, Yamazaki C, <b>Nakayama E</b> and <b>Udono H</b> .	Immune-mediated anti-tumor effect by type 2 diabetes drug, metformin.	Pros Natl Acad Sci USA	112	1809-14	2015

Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, <b><u>Kakimi K</u></b> .	Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN- $\gamma$ -dependent cell cycle arrest.	Cancer Immunol Res.	3	26-36	2015
Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, Shand FH, <b><u>Kakimi K</u></b> , Ito S, Matshushima K.	Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice.	Cancer Immunol Res.	20	Epub ahead of print	2015
Suzuki S, <b><u>Ishida T</u></b> , Yoshikawa K, <b><u>Ueda R</u></b> .	Progress in clinical use of CCR4 antibody for regulatory T cell suppression.	Inflammation and Immunity in Cancer.		207-27	2015
<b><u>Ueda R</u></b> , Suzuki S, Yoshikawa K, <b><u>Ishida T</u></b> ;	Clinical application of anti-CCR4 monoclonal antibody. Recent advances in cancer immunotherapy.	Recent advances in cancer immunotherapy		82-7	2014
Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, <b><u>Oka M</u></b> and <b><u>Nakayama E</u></b>	Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an anti-human CCR4 mAb (KM2760)	J. Thor. Oncol.	10	74-83	2014
Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, Fukuda M, Uenaka A, <b><u>Oka M</u></b> and <b><u>Nakayama E</u></b> .	Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.	Clin. Cancer Res	20	5052-63	2014
Ohue Y, <b><u>Wada H</u></b> , <b><u>Oka M</u></b> and <b><u>Nakayama E</u></b>	Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.	OncoImmunology	3	e970032	2014
Pandey, J, Namboodiri, A, Ohue, Y, <b><u>Oka, M</u></b> , <b><u>Nakayama, E</u></b> .	Genetic variants of immunoglobulin and chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.	Clin Exp Immunol	176	78-83	2014

Uehara T, Fujiwara T, Takeda K, Kunisada T, Ozaki T, <b><u>Udono H</u></b>	Immunotherapy for Bone and Soft Tissue Sarcomas.	BioMed Research International		Article ID 820813	2014
Ichiyanagi T, Ichiyanagi K, Ogawa A, Kuramochi-Miyagawa S, Nakano T, Chuma S, Sasaki H, <b><u>Udono H</u></b>	HSP90 plays an important role in piRNA biogenesis and retrotransposon repression in mouse.	Nucleic Acids Res.	42	11903-11	2014
Eikawa S, <b><u>Udono H</u></b>	Monitoring multifunctionality of immune-exhausted CD8 T cells in cancer bearing patients.	Methods in Mol Biol.	1142	11-7	2014
<b><u>Wada H</u></b> , Isobe M, <b><u>Kakimi K</u></b> , Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, <b><u>Udono H</u></b> , Seto Y, Yamada K, <b><u>Nishikawa H</u></b> , Pan L, Venhaus R, <b><u>Doki Y</u></b> , <b><u>Oka M</u></b> , <b><u>Nakayama E</u></b>	Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing NY-ESO-1 antigen.	J. of Immunotherapy.	37	84-92	2014
Maeda Y, <b><u>Nishikawa H</u></b> , Sugiyama D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I and Shakaguchi S.	Regulatory T cells drive autoimmune T cells into a distinct T-cell subpopulation functionally anergic and expressing CTLA-4.	Science.	346	1536-40	2014
Matsumoto M, Baba A, Yokota T, <b><u>Nishikawa H</u></b> , Ohkawa Y, Kayama H, Kallies A, Nutt SL, Sakaguchi S, Takeda K, Kurosaki T and Baba Y.	Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation.	Immunity	41	1040-51	2014
<b><u>Nishikawa H</u></b> , Sakaguchi S	Regulatory T cells in cancer immunotherapy	Curr Opin Immunol.	27	1-7	2014

Ito Y, Hashimoto M, Hirota K, Ohkura N, Morikawa H, <b><u>Nishikawa H</u></b> , Tanaka A, Furu M, Ito H, Fujii T, Nomura T, Yamazaki S, Morita A, Vignali DAA, Kappler JW, Matsuda S, Mimori T, Sakaguchi N and Sakaguchi S.	Detection of T-cell responses to a ubiquitous cellular protein in autoimmune disease.	Science.	346	363-8	2014
Saito T, Wada H, Yamasaki M, Miyata H, <b><u>Nishikawa H</u></b> , Sato E, Kageyama S, Shiku H, Mori M, <b><u>Doki Y</u></b> .	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine	Vaccine	32	5901-7	2014
Mizote Y, Uenaka A, Iisobe M, <b><u>Wada H</u></b> , <b><u>Kakimi K</u></b> , Saika T, Kita S, Koide Y, <b><u>Oka M</u></b> , <b><u>Nakayama E</u></b>	Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.	Vaccine	32	957-64	2014
Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, <b><u>Kakimi K</u></b> , Kume H, Ishikawa S, Homma Y, Fukayama M.	Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer	Ann Surg Oncol.	21	2105-12	2014
Wada I, Matsushita H, Noji S, Mori K, Yamasaki H, Nomura S, Shimizu N, Seto Y, <b><u>Kakimi K</u></b> .	Intraperitoneal injection of in vitro expanded V $\gamma$ 9V $\delta$ 2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.	Cancer Med.	3	362-75	2014
Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, <b><u>Kakimi K</u></b> .	Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.	Int J Cancer.	134	1810-22.	2014
Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, <b><u>Kakimi K</u></b> .	Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.	Mol Clin Oncol.	2	1023-27	2014

Matsushita H, Enomoto H, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y and <b><u>Kakimi K.</u></b>	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.	J Immunother Cancer.	2	30	2014
Futami J, Fujiyama H, Kinoshita R, Nonomura H, Honjo T, Tada H, Matsushita H, Abe Y, <b><u>Kakimi K.</u></b>	Denatured mammalian proteins in mixtures exhibit unusually high solubility in nucleic acid-free pure water.	PLoS One.	9	e113295	2014
Kobayashi T, <b><u>Kakimi K.</u></b> , <b><u>Nakayama E.</u></b> , Jimbow K.	Antitumor immunity by magnetic nanoparticle-mediated hyperthermia.	Nanomedicine (Lond)	9	1715-26	2014
Ogura M, <b><u>Ishida T.</u></b> , Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, <b><u>Ueda R.</u></b>	Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.	J Clin Oncol.	32	1157-63	2014
Narita T, <b><u>Ishida T.</u></b> , Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Masaki R, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, <b><u>Iida S.</u></b> , <b><u>Ueda R.</u></b>	HTLV-1 bZIP factor specific CD4 T cell responses in ATL patients after allogeneic hematopoietic stem cell transplantation.	J Immunol.	192	940-7	2014
Mizote Y, Wakamatsu K, Ito S, Uenaka A, Ohue Y, Kurose K, Isobe M, Ito A, Tamura Y, Honda H, Yamashita T, Nohara S, <b><u>Oka M.</u></b> , Jimbow K, and <b><u>Nakayama E.</u></b>	TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteamine phenol-maleimide-dextran (NPCMD).	J Dermatol Sci,	73	209-15	2014
Mizote Y, Uenaka A, Isobe M, Wada H, <b><u>Kakimi K.</u></b> , Saika T, Kita S, Koide Y, <b><u>Oka M.</u></b> , and <b><u>Nakayama E.</u></b>	Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.	Vaccine	32	957-64	2014

Wada H, Isobe M, <b>Kakimi K</b> , Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, <b>Udono H</b> , Seto Y, Yamada K, <b>Nishikawa H</b> , Pan L, Venhaus R, <b>Oka M</b> , <b>Doki Y</b> , <b>Nakayama E</b> .	Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.	J Immunother	37	84-92	2014
Nakano N, Kusumoto S, Tanaka Y, <b>Ishida T</b> , Takeda S, Takatsuka Y, Akinaga S, Mizokami M, <b>Ueda R</b> , Utsunomiya A.	Utsunomiya A. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.	Hepatol Res.	44	354-7	2014
Mori F, <b>Ishida T</b> , Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, <b>Ueda R</b> , Inagaki H, <b>Iida S</b> .	Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model.	Eur J Haematol.	92	219-28	2014
Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, <b>Iida S</b> , Kuroda Y, Sakai A, Ziepert M, <b>Ueda R</b> , Pfreundschuh M, Preuss K-D.	Over one third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal-dominantly inherited risk factor for MGUS/MM.	Int J Cancer		Epub ahead of print.	2014
Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, Ri M, <b>Ishida T</b> , <b>Ueda R</b> , Utsunomiya A, Asai K, Inagaki H.	Prognostic impact of miR-145 down-regulation in adult T-cell leukemia/lymphoma.	Human Pathol	45	1192-8	2014

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
河上 裕、 <b>上田龍三</b>	新たな時代を迎えたがん免疫療法	Immuno-Oncology Frontier,	1	1	2015
<b>西川博喜</b> 、坂口志文	ヒト制御性T細胞の解析	医学のあゆみ	252	69-74	2015

黒瀬浩史, <u>岡 三喜男</u> , <u>中山書一</u>	抗CCR4抗体の制御性T細胞への影響と臨床応用の可能性	最新医学	70	393-8	2015
<u>西川博嘉</u>	Visual View がん免疫療法のメカニズム	Immuno-Oncology Frontier	1	10-3	2015
<u>和田 尚</u>	抗PD-1抗体の泌尿器科疾患, 消化器疾患への応用	最新医学	70	421-7	2015
鈴木 進, <u>石田 高司</u> , 吉川 和宏, <u>上田 龍三</u> :	モガムリズマブ	The Frontiers in Life Sciences. 生命科学から創薬へのイノベーション		183-95	2014
<u>上田龍三</u>	第6回モガムリズマブサミライたちのクスリ(PAR T II)	Medical AS AHI	12	78-81	2014
黒瀬浩史, <u>岡 三喜男</u> , <u>中山書一</u>	基礎: 抗CCR4抗体の制御性T細胞への影響と臨床応用の可能性	最新医学	70	393-8	2014
<u>岡 三喜男</u> , 大植祥弘, 黒瀬浩史, <u>中山書一</u>	特集: これから期待される肺癌診断と治療: 抗体免疫療法	呼吸器内科	26	431-7	2014
<u>岡 三喜男</u> , 大植祥弘, 黒瀬浩史, <u>中山書一</u>	がん精巣抗原に対する免疫応答とその臨床的意義	BIO Clinica	30	31-5	2014
杉山大介, <u>西川博嘉</u>	制御性T細胞および免疫チェックポイント分子の解除による抗腫瘍免疫応答増強の可能性	がん分子標的治療	12	84-8	2014
<u>西川博嘉</u>	制御性T細胞とがん免疫療法	臨床血液	55	475-81	2014
榮川伸吾, <u>鶴殿平一郎</u>	T細胞の免疫疲弊と免疫チェックポイント分子	最新医学	70	62-68	2014